Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial-Reference-Cited by-同舟云学术

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Published:2018-06 Issue:10139 Volume:391 Page:2513-2524
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Genovese Mark C,Fleischmann Roy,Combe Bernard,Hall Stephen,Rubbert-Roth Andrea,Zhang Ying,Zhou Yijie,Mohamed Mohamed-Eslam F,Meerwein Sebastian,Pangan Aileen L

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

3. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group;Lipsky;N Engl J Med,2000

4. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial;Smolen;Lancet,2009

Cited by 355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review;Leukemia Research;2024-11

2. Direct Enantioselective α-C–H Conjugate Addition of Propargylamines to α,β-Unsaturated Ketones via Carbonyl Catalysis;Journal of the American Chemical Society;2024-09-11

3. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

4. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis;Clinical Rheumatology;2024-09-07

5. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis;PLOS ONE;2024-07-31